ArticleFuture oncology (London, England)2026
Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma.
Reinhard Dummer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.